21:30 , Mar 11, 2019 |  BC Extra  |  Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

Seres gained $1.27 (25%) to $6.38 on Monday after it announced a three-year partnership with AstraZeneca to evaluate microbiome-based approaches to improve and predict patient response to immunotherapies. Seres Therapeutics Inc. (NASDAQ:MCRB) will receive $20...
00:15 , Mar 9, 2019 |  BC Extra  |  Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy....
19:10 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

USP11 identified as a prostate cancer target

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Patient sample and cell culture studies suggest promoting USP11 expression could help treat prostate cancer. In prostate tissue samples from patients, levels of USP11 protein were lower than in...
21:37 , Feb 14, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
20:40 , Jan 18, 2019 |  BC Week In Review  |  Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
13:46 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Renal cancer; lung cancer Cell culture and mouse studies suggest inhibiting PGD alone or in combination with OXPHOS complex I inhibition could help treat renal cell carcinoma (RCC) or non-small cell lung cancer (NSCLC),...
00:50 , Jan 15, 2019 |  BC Extra  |  Politics & Policy

MSKCC says senior execs may not hold industry board seats

Memorial Sloan Kettering Cancer Center has barred its senior executive officers from holding board positions at MSKCC spinouts or external for-profit health and science-related entities, according to a staff memo sent by SVP and Chief...
22:44 , Jan 7, 2019 |  BC Extra  |  Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

As the biopharma industry awaits guidance from the government on the scope and potential impact of proposed technology export controls, a new congressional bill could help speed the process. Members of the Senate Select Committee...
20:19 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

No breakthrough therapy designation for Spectrum's poziotinib

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) lost $4.05 (39%) to $6.39 on Dec. 20 after announcing after market close on Dec. 19 that based on data from an investigator-sponsored Phase II trial FDA did not grant breakthrough...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...